Telmisartan Versus Ramipril After Acute Coronary Syndrome (TERACS)

Catholic University of the Sacred Heart

Status and phase: Unknown; Phase 4

Conditions: Acute Coronary Syndrome; Myocardial Infarction; Coronary Disease

Treatments: Drug: TELMISARTAN; Drug: RAMIPRIL

Study type: Interventional

Funder types: Other

Identifiers

NCT00702936

ILG-1

Details and patient eligibility

About

The purpose of this study is to compare the antinflammatory and endothelial progenitor cell (EPC) mobilizing effect of Ramipril and Telmisartan in patients presenting with acute coronary syndrome

Enrollment: 50 estimated patients

Sex: All

Ages: 40 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Biochemical evidence of myocardial infarction as indicated by elevation of cTnT,
• presence of ECG ischemic changes,
• angiographic evidence of a primary coronary event, such as plaque erosion and/or rupture, fissuring, or dissection at coronary angiography,
• successful coronary revascularization of at least one culprit coronary vessel.

Exclusion criteria

• Age>80 years, current ACE inhibitor or ARB treatment,
• ejection fraction <35%, infarction secondary to ischemia due to an imbalance of O2 supply and demand,
• ECG abnormalities that could affect the recognition of ST segment shift,
• recent or chronic infective or inflammatory diseases,
• malignancy, and myocardial infarction,
• surgery or trauma in the previous month.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

50 participants in 2 patient groups

R

Active Comparator group

Description:

Twenty-five patients assigned to ramipril 5 mg daily

Treatment:

Drug: RAMIPRIL

T

Active Comparator group

Description:

Twenty-five patients assigned to Telmisartan 80 mg daily

Treatment:

Drug: TELMISARTAN